UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Toward precision prescribing for methadone: Determinants of methadone deposition

PloS one, 2020-04, Vol.15 (4), p.e0231467

2020

Link zum Volltext

Verfügbarkeit prüfen

Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease

Movement disorders, 2022-02, Vol.37 (2), p.334-342

2022

Link zum Volltext

Verfügbarkeit prüfen

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Lancet neurology, 2017-11, Vol.16 (11), p.908-916

2017

Link zum Volltext

Verfügbarkeit prüfen

Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design

Movement disorders, 2023-10, Vol.38 (10), p.1774-1785

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic approaches to the treatment of Huntington's disease

Movement disorders, 2012-01, Vol.27 (1), p.31-41

2012

Link zum Volltext

Verfügbarkeit prüfen

A review of disease progression models of Parkinson's disease and applications in clinical trials

Movement disorders, 2016-07, Vol.31 (7), p.947-956

2016

Link zum Volltext

Verfügbarkeit prüfen

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease

Annals of clinical and translational neurology, 2021-03, Vol.8 (3), p.603-612

2021

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease

Movement disorders clinical practice (Hoboken, N.J.), 2022-10, Vol.9 (7), p.961-966

2022

Link zum Volltext

Verfügbarkeit prüfen

Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

Analytical methods, 2020-04, Vol.12 (14), p.1882-1888

2020

Link zum Volltext

Verfügbarkeit prüfen

Correction: Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

Analytical methods, 2020-05, Vol.12 (16), p.2196-2196

2020

Link zum Volltext

Verfügbarkeit prüfen

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

Clinical pharmacology and therapeutics, 2021-08, Vol.110 (2), p.508-518

2021

Link zum Volltext

Verfügbarkeit prüfen

Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy

The Journal of infectious diseases, 2020-07, Vol.222 (4), p.601-610

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment

Clinical pharmacology in drug development, 2017-03, Vol.6 (2), p.206-212

2017

Link zum Volltext

Verfügbarkeit prüfen

Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s

Antiviral therapy, 2018-01, Vol.23 (4), p.345-351

2018

Link zum Volltext

Verfügbarkeit prüfen

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus‐1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub‐study A5334s

British journal of clinical pharmacology, 2020-01, Vol.86 (1), p.132-142

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation

Liver transplantation, 2016-03, Vol.22 (3), p.287-297

2016

Link zum Volltext

Verfügbarkeit prüfen

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders

Current vascular pharmacology, 2016-05, Vol.14 (3), p.280

2016

Link zum Volltext

Verfügbarkeit prüfen

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

Journal of antimicrobial chemotherapy, 2017-07, Vol.72 (7), p.2042-2048

2017

Link zum Volltext

Verfügbarkeit prüfen

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Link zum Volltext

Verfügbarkeit prüfen

Developing better digital health measures of Parkinson's disease using free living data and a crowdsourced data analysis challenge

PLOS digital health, 2023-03, Vol.2 (3), p.e0000208-e0000208

2023

Link zum Volltext

Verfügbarkeit prüfen

Oral Ketamine for Children with Chronic Pain: A Pilot Phase 1 Study

The Journal of pediatrics, 2013-07, Vol.163 (1), p.194-200.e1

2013

Link zum Volltext

Verfügbarkeit prüfen

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology

Clinical pharmacology in drug development, 2017-03, Vol.6 (2), p.169-175

2017

Link zum Volltext

Verfügbarkeit prüfen

A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson’s Disease Clinical Trial: A Pilot Study

Digital biomarkers, 2022, Vol.6 (1), p.1-8

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct‐Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

Clinical pharmacology in drug development, 2017-03, Vol.6 (2), p.135-139

2017

Link zum Volltext

Verfügbarkeit prüfen

Advocacy Recruiting for Huntington's Disease Clinical Trials

PLoS currents, 2011-04, Vol.3, p.RRN1230-RRN1230

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(54)
Tagungsberichte
(1)

Sprache

Englisch
(55)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(41)
Humans
(32)
Male
(24)
Female
(23)
Pharmacology & Pharmacy
(18)
Neurosciences & Neurology
(16)
Middle Aged
(15)
Adult
(14)
Clinical Neurology
(14)
Hiv
(9)
Biomarkers
(8)
Clinical Trials
(8)
Human Immunodeficiency Virus
(8)
Parkinson's Disease
(8)
Aged
(7)
Pharmacokinetics
(7)
Acquired Immunodeficiency Syndrome - Drug Therapy
(6)
Disease Progression
(6)
Hiv Infections - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Toward precision prescribing for methadone: Determinants of methadone deposition

Re‐Analysis of the STEADY‐PD II Trial—Evidence for Slowing the Progression of Parkinson's Disease

Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design

Pharmacologic approaches to the treatment of Huntington's disease

A review of disease progression models of Parkinson's disease and applications in clinical trials

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease

Prevalence and Incidence of Nonmotor Symptoms in Individuals with and Without Parkinson's Disease

Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

Correction: Towards simultaneous quantification of protease inhibitors and inflammatory biomarkers in serum for people living with HIV

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy

Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment

Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s

Raltegravir pharmacokinetics before and during treatment with ombitasvir, paritaprevir/ritonavir plus dasabuvir in adults with human immunodeficiency virus‐1 and hepatitis C virus coinfection: AIDS Clinical Trials Group sub‐study A5334s

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques

Developing better digital health measures of Parkinson's disease using free living data and a crowdsourced data analysis challenge

Oral Ketamine for Children with Chronic Pain: A Pilot Phase 1 Study

Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology

A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson’s Disease Clinical Trial: A Pilot Study

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct‐Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

Advocacy Recruiting for Huntington's Disease Clinical Trials

Suchergebnisse filtern